De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Syngene International Toekomstige groei
Future criteriumcontroles 3/6
Syngene International zal naar verwachting groeien in winst en omzet met respectievelijk 17.4% en 14.3% per jaar. De winst per aandeel zal naar verwachting groeien met 16.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.2% zijn.
Belangrijke informatie
17.4%
Groei van de winst
16.5%
Groei van de winst per aandeel
Life Sciences winstgroei | 20.8% |
Inkomstengroei | 14.3% |
Toekomstig rendement op eigen vermogen | 13.2% |
Dekking van analisten | Good |
Laatst bijgewerkt | 30 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Is Syngene International (NSE:SYNGENE) Using Too Much Debt?
Aug 28Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate
Aug 10These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well
May 10Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Feb 02Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Nov 26Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly
Sep 21Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock
Aug 06Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2027 | 51,176 | 7,889 | 4,248 | N/A | 6 |
3/31/2026 | 44,722 | 6,871 | 3,807 | N/A | 8 |
3/31/2025 | 38,228 | 5,642 | 2,806 | N/A | 8 |
6/30/2024 | 34,702 | 4,923 | N/A | N/A | N/A |
3/31/2024 | 34,886 | 5,100 | 5,313 | 10,421 | N/A |
12/31/2023 | 35,661 | 5,002 | N/A | N/A | N/A |
9/30/2023 | 34,985 | 4,984 | 4,706 | 10,290 | N/A |
6/30/2023 | 33,565 | 4,839 | N/A | N/A | N/A |
3/31/2023 | 31,929 | 4,644 | 3,052 | 8,235 | N/A |
12/31/2022 | 29,566 | 4,334 | N/A | N/A | N/A |
9/30/2022 | 28,121 | 4,277 | 1,083 | 5,898 | N/A |
6/30/2022 | 26,542 | 3,924 | N/A | N/A | N/A |
3/31/2022 | 26,042 | 3,958 | 1,051 | 5,806 | N/A |
12/31/2021 | 25,047 | 4,086 | N/A | N/A | N/A |
9/30/2021 | 24,478 | 4,068 | 2,102 | 6,566 | N/A |
6/30/2021 | 23,572 | 4,242 | N/A | N/A | N/A |
3/31/2021 | 21,843 | 4,049 | 2,547 | 7,012 | N/A |
12/31/2020 | 21,330 | 3,645 | N/A | N/A | N/A |
9/30/2020 | 20,676 | 3,541 | 1,217 | 6,318 | N/A |
6/30/2020 | 20,126 | 3,981 | N/A | N/A | N/A |
3/31/2020 | 20,119 | 4,121 | 340 | 6,771 | N/A |
12/31/2019 | 19,385 | 3,920 | N/A | N/A | N/A |
9/30/2019 | 18,865 | 3,872 | 1,257 | 7,549 | N/A |
6/30/2019 | 18,405 | 3,374 | N/A | N/A | N/A |
3/31/2019 | 18,256 | 3,316 | 471 | 6,304 | N/A |
12/31/2018 | 17,008 | 3,160 | N/A | N/A | N/A |
9/30/2018 | 16,214 | 3,110 | N/A | N/A | N/A |
6/30/2018 | 15,380 | 3,096 | N/A | N/A | N/A |
3/31/2018 | 14,231 | 3,054 | N/A | 4,462 | N/A |
12/31/2017 | 13,053 | 2,993 | N/A | N/A | N/A |
9/30/2017 | 12,497 | 2,917 | N/A | N/A | N/A |
6/30/2017 | 12,175 | 2,895 | N/A | N/A | N/A |
3/31/2017 | 12,009 | 2,873 | N/A | 3,977 | N/A |
12/31/2016 | 12,411 | 2,682 | N/A | N/A | N/A |
9/30/2016 | 11,894 | 2,606 | N/A | N/A | N/A |
6/30/2016 | 11,479 | 2,344 | N/A | N/A | N/A |
3/31/2016 | 11,070 | 2,408 | N/A | 3,081 | N/A |
12/31/2015 | 10,235 | 2,103 | N/A | N/A | N/A |
9/30/2015 | 9,713 | 1,964 | N/A | N/A | N/A |
6/30/2015 | 9,017 | 1,843 | N/A | N/A | N/A |
3/31/2015 | 8,599 | 1,750 | N/A | 185 | N/A |
3/31/2014 | 6,995 | 1,339 | N/A | 2,995 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei SYNGENE ( 17.4% per jaar) ligt boven de spaarquote ( 6.7% ).
Winst versus markt: De winst van SYNGENE ( 17.4% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 17.3% per jaar).
Hoge groeiwinsten: De winst van SYNGENE zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van SYNGENE ( 14.3% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.1% per jaar).
Hoge groei-inkomsten: De omzet van SYNGENE ( 14.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen SYNGENE zal naar verwachting over 3 jaar laag zijn ( 13.2 %).